AR111412A1 - Formas cristalinas de (s)-afoxolaner - Google Patents

Formas cristalinas de (s)-afoxolaner

Info

Publication number
AR111412A1
AR111412A1 ARP180100859A ARP180100859A AR111412A1 AR 111412 A1 AR111412 A1 AR 111412A1 AR P180100859 A ARP180100859 A AR P180100859A AR P180100859 A ARP180100859 A AR P180100859A AR 111412 A1 AR111412 A1 AR 111412A1
Authority
AR
Argentina
Prior art keywords
afoxolaner
crystal forms
diffractometer
crystals
radiation
Prior art date
Application number
ARP180100859A
Other languages
English (en)
Inventor
De Vries Roelof Johannes Gorter
Stphane Kozlovic
De Saint Michel Myriam Gay
Bruno Baillon
Sylvaine Lafont
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of AR111412A1 publication Critical patent/AR111412A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Secondary Cells (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Reivindicación 1: Un compuesto cristalino de fórmula (1), caracterizado porque está designado como Forma I, donde dichos cristales se caracterizan porque tienen un patrón de difracción de rayos X de polvo que comprende tres, cuatro, cinco, seis, siete o más picos seleccionados entre el grupo que consiste en: 10,03º, 10,48º, 13,16º, 15,42º, 15,80º, 16,07º, 17,65º, 20,16º, 22,15º, 23,68º, 26,52º y 28,13º 2q ± 0,2 según se determina con un difractómetro que usa radiación Cu-Ka. Reivindicación 11: Un compuesto. cristalino de fórmula (1), caracterizado porque está designado como Forma II, donde dichos cristales se caracterizan porque tienen un patrón de difracción de rayos X de polvo que comprende tres, cuatro, cinco, seis, siete o más picos seleccionados entre el grupo que consiste en: 5,99º, 12,99º, 15,80º, 18,71º, 19,33º, 20,24º, 21,65º, 22,17º, 26,11º y 29,00º 2q ± 0,2 según se determina con un difractómetro que usa radiación Cu-Ka.
ARP180100859A 2017-04-05 2018-04-05 Formas cristalinas de (s)-afoxolaner AR111412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
AR111412A1 true AR111412A1 (es) 2019-07-10

Family

ID=62092252

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100859A AR111412A1 (es) 2017-04-05 2018-04-05 Formas cristalinas de (s)-afoxolaner

Country Status (23)

Country Link
US (2) US10662163B2 (es)
EP (1) EP3606911A1 (es)
JP (1) JP7222909B2 (es)
KR (1) KR102612648B1 (es)
CN (1) CN111032634A (es)
AR (1) AR111412A1 (es)
AU (1) AU2018250304B2 (es)
BR (1) BR112019021072A2 (es)
CA (1) CA3059114A1 (es)
CL (1) CL2019002840A1 (es)
CO (1) CO2019011980A2 (es)
EA (1) EA201992360A1 (es)
IL (1) IL269792B (es)
MD (1) MD20190080A2 (es)
MX (1) MX2019011931A (es)
MY (1) MY188420A (es)
PH (1) PH12019502277A1 (es)
SG (1) SG11201909229SA (es)
TW (1) TWI782976B (es)
UA (1) UA125727C2 (es)
UY (1) UY37665A (es)
WO (1) WO2018187623A1 (es)
ZA (1) ZA201906464B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125727C2 (uk) * 2017-04-05 2022-05-25 Бьорінґер Інґельхайм Енімал Хелт Юесей Інк. Кристалічні форми (s)-афоксоланеру
CN115768753B (zh) * 2020-06-19 2024-04-26 东莞市东阳光动物保健药品有限公司 一种gaba抑制剂的晶型及其制备方法
CN118536571A (zh) * 2024-05-31 2024-08-23 北京无问芯穹科技有限公司 一种构建扩散变换器模型的方法、系统、设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI461411B (zh) * 2007-08-17 2014-11-21 Du Pont 製備５－鹵烷基－４，５－二氫異唑衍生物之方法
HUE028501T2 (en) * 2010-05-27 2016-12-28 Du Pont 4- [5- [3-Chloro-5- (trifluoromethyl) phenyl] -4,5-dihydro-5- (trifluoromethyl) -3-isoxazolyl] -N- [2-oxo-2 - [(2.2, 2-Trifluoroethyl) amino] ethyl] -1-naphthalenecarboxamide crystalline form
EP3788874A1 (en) * 2011-09-12 2021-03-10 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, method and uses thereof
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
JP6824900B2 (ja) * 2015-04-08 2021-02-03 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド イソオキサゾリン活性薬剤を含む延長放出注射製剤、方法及びその使用
KR102403531B1 (ko) * 2016-04-06 2022-05-27 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 거울상 이성질체적으로 풍부한 이속사졸린 화합물의 제조 방법 및 (s)-아폭솔라너의 결정질 톨루엔 용매화물
UA125727C2 (uk) * 2017-04-05 2022-05-25 Бьорінґер Інґельхайм Енімал Хелт Юесей Інк. Кристалічні форми (s)-афоксоланеру

Also Published As

Publication number Publication date
PH12019502277A1 (en) 2020-09-14
KR20190136055A (ko) 2019-12-09
UY37665A (es) 2018-10-31
MX2019011931A (es) 2020-01-13
US20180354917A1 (en) 2018-12-13
AU2018250304B2 (en) 2022-03-03
MD20190080A2 (ro) 2020-04-30
JP2020513010A (ja) 2020-04-30
KR102612648B1 (ko) 2023-12-11
US11130739B2 (en) 2021-09-28
UA125727C2 (uk) 2022-05-25
TW201841895A (zh) 2018-12-01
WO2018187623A1 (en) 2018-10-11
CA3059114A1 (en) 2018-10-11
SG11201909229SA (en) 2019-11-28
US10662163B2 (en) 2020-05-26
CO2019011980A2 (es) 2020-02-18
MY188420A (en) 2021-12-08
EA201992360A1 (ru) 2020-09-02
WO2018187623A8 (en) 2019-10-24
IL269792A (en) 2019-11-28
ZA201906464B (en) 2021-08-25
TWI782976B (zh) 2022-11-11
IL269792B (en) 2022-04-01
AU2018250304A1 (en) 2019-10-31
US20200270219A1 (en) 2020-08-27
BR112019021072A2 (pt) 2020-05-12
CN111032634A (zh) 2020-04-17
EP3606911A1 (en) 2020-02-12
CL2019002840A1 (es) 2020-01-10
JP7222909B2 (ja) 2023-02-15

Similar Documents

Publication Publication Date Title
AR111412A1 (es) Formas cristalinas de (s)-afoxolaner
IL271631A (en) Deuterium compounds and their use
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
CL2016002033A1 (es) Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros.
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
SI3152212T1 (sl) Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
AR090151A1 (es) Compuestos inhibidores de raf
PE20141061A1 (es) Compuesto inhibidor de la senalizacion de la trayectoria notch
EP3466934A4 (en) SULPHONAMIDE COMPOUND OR SALT THEREOF
AR082804A1 (es) Formas cristalinas de un inhibidor del factor xa
AR103902A1 (es) Métodos para preparar buprenorfina
WO2018004315A3 (ko) 화합물 및 이를 포함하는 유기 전자 소자
UY37119A (es) Imidazolil–carboxamidas sustituidas como plaguicidas
UY37117A (es) 2–oxiimidazolil–carboxamidas sustituidas como plaguicidas
UY37116A (es) Imidazolil–carboxamidas sustituidas como plaguicidas
WO2015017378A3 (en) Novel copper-cysteamine and methods of use
WO2014160218A3 (en) Pigments of simultaneously substituted pyrochlore and related structures
UY35707A (es) ?compuestos pirrolónicos, procesos e intermediarios para prepararlos, composiciones y métodos de uso?.
HUE054883T2 (hu) N-{5-[(6,7-dimetoxi-4-kinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-kinolinkarboxamid etánszulfonát sója
SG11202106210QA (en) Salt of syk inhibitor and crystalline form thereof
AR099082A1 (es) Formas sólidas de tenofovir
IL272835A (en) Salts of a compound and crystalline forms thereof
AR109079A1 (es) Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)1h-imidazol-2-carboxamida
WO2015044960A3 (en) Compounds for inhibition of unregulated cell growth
RU2015146088A (ru) Синергетическая комбинация флурохлоридона и пиритиона цинка для защиты сухих пленок